Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

INTRODUCTION: Despite extensive multidisciplinary team (MDT) assessment, some patients have interstitial lung disease (ILD) that is considered unclassifiable (uILD), for which there are currently no approved treatments. This study will assess the efficacy and safety of the antifibrotic pirfenidone i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMJ Open Respir Res
Main Authors: Maher, Toby M, Corte, Tamera J, Fischer, Aryeh, Kreuter, Michael, Lederer, David J, Molina-Molina, Maria, Axmann, Judit, Kirchgaessler, Klaus-Uwe, Cottin, Vincent
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2018
Teme:
Interstitial Lung Disease
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135451/
https://ncbi.nlm.nih.gov/pubmed/30233802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2018-000289
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki